Intra-Cellular Therapies, Inc. (ITCI) は上場企業です ヘルスケア セクターの Drug Manufacturers - Specialty & Generic 業界で事業展開. 本社所在地は New York City, NY, アメリカ. 現CEOは Sharon Mates.
ITCI を有する IPO日 2014-01-07, 860 名の正社員, に上場 NASDAQ Global Select, 時価総額 $14.05B.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company headquartered in New York that develops novel medications for neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms in the central nervous system. The company's approved product CAPLYTA treats schizophrenia in adults, while its clinical pipeline includes lumateperone in Phase III trials for bipolar depression and autism spectrum disorder, Lenrispodun for Parkinson's disease and heart failure, ITI-1284-ODT-SL for dementia-related behavioral disturbances, and ITI-333 for substance use disorders and psychiatric conditions. Founded in 2002, the company focuses on addressing significant unmet medical needs in the neuropsychiatric market through innovative drug development.
